Valneva SE (0OB3.L)

4.8143 -0.0096 (-0.20%) At close: 05:59PM BST

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Sector(s): 
Industry: 
Full-time employees: 762

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thomas Lingelbach	Chairman of the Management Board, Pres & CEO	769.14k	N/A	1963
Mr. Franck Grimaud MBA	Director Gen., Chief Bus. Officer & Member of Management Board	482.35k	N/A	1967
Mr. Frederic Jacotot	VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board	378.59k	N/A	1965
Dr. Juan-Carlos Jaramillo M.D.	Chief Medical Officer & Member of the Management Board	527.17k	N/A	1972
Mr. Peter Buhler	CFO & Management Board Member	N/A	N/A	1971
Mr. Perry Celentano	Interim Chief Operating Officer	N/A	N/A	N/A
Ms. Dipal Patel	Chief Commercial Officer & Member of Management Board	N/A	N/A	N/A
Mr. Joshua Drumm Ph.D.	VP of Investor Relations	N/A	N/A	N/A
Ms. Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	N/A	N/A	N/A
Mr. Gerald Strohmaier	VP of Human Resource	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Corporate governance

Valneva SE’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.